Skip to main content
UTHR logo

UTHR · UNITED THERAPEUTICS Corp

Track UTHR — free
$586.15 -5.02 (-0.85%)
Market Cap
$25.18B
Shares
42.59M
Volume · Nov 16 165.24K Avg daily vol (3M) 700.23K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$591.17 Open$593.31 Day$587.00–598.84 52W close$462.30–608.49 Avg vol 30d637K Short int1.8M · 4.3% of shares · 3.5d Short vol44% Last earningsNov 4, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Feb 24, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 4
Current report 8-K
Revenue rises while net income declines

United Therapeutics reported $832.5 million in revenue for the quarter ended September 30, 2026, versus $799.5 million, while net income declined to $258.6 million from $338.7 million.

Financial results
3 source passages
Total revenues in the third quarter of 2026 increased by four percent year-over-year to $832.5 million, compared to $799.5 million in the third quarter of 2025. Net income | 258.6 | | | 338.7 | | | (80.1) | | | (24)% United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2026. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Liquidia settlement targets Yutrepia’s PH-ILD competition

United Therapeutics said Liquidia must remove PH-ILD from Yutrepia’s label after an adverse patent ruling and agreed to pay $330.4 million for past and future damages; Nebulized Tyvaso’s IPF application has an FDA goal date of April 26, 2027.

Revenue $832.5M ▲ 4.1% Net income $258.6M ▼ 23.6% Diluted EPS $5.71 ▼ 20.3%
Read from the MD&A section
5 source passages
On September 30, 2026, the District Court ruled that Liquidia’s product infringes two valid claims of this patent. As a result of this decision, on October 1, 2026, Liquidia filed a supplement to its NDA to remove the PH-ILD indication from the Yutrepia labeling. Under our settlement agreement with Liquidia, Liquidia is required to diligently seek approval of this updated label. Under our settlement agreement with Liquidia, Liquidia also agreed to pay us $330.4 million as an estimate of past and future damages resulting from infringing sales of its product. In September 2026, we were notified that the FDA had accepted our sNDA with a user fee goal date of April 26, 2027. Open the document at this passage
Oct 22
Current report 8-K Events of Oct 21
Other events

On October 21, 2026, United Therapeutics Corporation’s Board authorized repurchases of up to $2.0 billion of common stock through October 21, 2027; the company announced the program on October 22, 2026.

Oct 14
Current report 8-K Events of Oct 13
Other events

United Therapeutics and Liquidia settled patent litigation on October 13, 2026; Liquidia will pay $330.4 million, while United Therapeutics will pay $10.0 million to settle the RareGen/Sandoz litigation. Liquidia must remove PH-ILD from Yutrepia labeling and cease related marketing.

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$3.19B
Trailing 12 months
Net income (TTM)
$1.23B
Trailing 12 months
Revenue growth YoY
+4.1%
Year over year
Operating margin
41.4%
Trailing 12 months
P / E (TTM)
22.3
Trailing earnings · reciprocal yield 4.5%
FCF yield
3.4%
TTM · current market cap
Return on invested capital
25.6%
Trailing 12 months
Net cash
$2.07B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-4.2%
Year over year · fewer shares
Price change (1Y)
+27.9%
Trailing year
Short interest
4.3%
Latest settlement · 3.5 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. Second-quarter revenue declined 2% year over year to $783.3 million, below expectations, while net income rose 8% to $333.0 million. The company expects a stronger second half but did not reaffirm or update its 2026 revenue-growth outlook, while potential 2027 approvals for Nebulized Tyvaso in IPF and ralinepag tablets in PAH remain important growth catalysts.

Bullish
  • + Net income increased 8% year over year to $333.0 million.
  • + Tyvaso DPI exited the quarter with record starts, referrals, commercial patients, and total patients.
  • + The company expects the second half of 2026 to be stronger than the first half.
  • + Potential 2027 approvals are expected for Nebulized Tyvaso in IPF and ralinepag tablets in PAH.
Bearish
  • − Second-quarter revenue declined 2% year over year to $783.3 million and was below expectations.
  • − The company did not reaffirm or update its 2026 revenue-growth expectations.
  • − The path to the previously projected $4 billion revenue run rate by the end of 2027 has narrowed.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross Golden cross
Price vs 200-day avg +10%
above
Price vs 50-day avg +9%
above
RSI (14) 58
neutral
MACD trend Negative
52-week position 88%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +11%
trailing
6-month return +2%
trailing
YTD return +21%
this year
Relative strength +2%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) Golden cross
50d $543 › 200d $537 — 50d above 200d
Institutional flow Accumulating
748 of 890 funds reported for Sep 30 · net +739.3K sh shares · +56 new
Insider flow Distributing
Net -$817.1K over 90 days · 100% sells
Short interest Falling
4.31% of shares out · ▼ -25.2% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
890 holders — near 3-yr high, broad support
Squeeze score 52
elevated · 0–100
Fundamentals
Excellent
Revenue growth +2%
Y/Y
Gross margin 189%
expanding
EPS growth +13%
Y/Y
Free cash flow $1.0B
Valuation P/E 22.3
below peers
Buyback $6.8B
authorized
Balance sheet $1.6B
net cash
Quant / Vol
risk profile
Moderate
Volatility 35%
annualized · 1-yr
Max drawdown −21%
past year
ATR 3.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed May 6, 2026
$4 billion run rate · by next year $4B
Previous outlook earlier release · from the Earnings Call filed Oct 29, 2025

Still-open targets the latest release did not restate under the same label.

Revenue run rate · not later than 2027 $4B

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 4
50 / 200-day cross
Golden cross Bullish
Price vs 200-day avg
+10% Bullish
Price vs 50-day avg
+9% Bullish
RSI (14)
58 Neutral
MACD trend
Negative Bearish
52-week position
88% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) Golden cross
50d $543 › 200d $537 — 50d above 200d
Institutional flow Accumulating
748 of 890 funds reported for Sep 30 · net +739.3K sh shares · +56 new
Insider flow Distributing
Net -$817.1K over 90 days · 100% sells
Short interest Falling
4.31% of shares out · ▼ -25.2% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
890 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $462 Now $591 · 88% Range high $608
vs 200-day avg +10% vs 50-day avg +9% 50-day above 200-day golden cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Remaining availability under share repurchase program $500M As of June 30, 2026 —
Shares repurchased under the 2026 ASR agreements 2,759,343 In total —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
UTHR
UNITED THERAPEUTICS Corp
this stock
$25.18B +21.3% +2.4% 22.3 4.3%
TAK
Takeda Pharmaceutical Co Ltd
$68.47B +37.5% — — 0.1%
GALDY
Galderma Group AG
$53.23B +10.1% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$51.92B +42.6% +4.3% 101.1 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
882
% held
99.7%
Reported
748 of 890
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
714
View
Short & Settlement
Short Interest Falling
Shares short
1.8M
Days to cover
3.5d
Change
-620.1K sh
View
Short Volume
Short vol %
44%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
57
Value
$33.4K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
49.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$817.1K
Buyers / Sellers
0 / 2
Buyers Sellers
View
Congressional Trades Sell
Member
Lisa McClain
Amount
$1.0K–$15.0K
Traded
Oct 31, 2025
View
Financials
Financials
Revenue (FY)
$3.2B
Net income (FY)
$1.3B
EPS diluted
$27.86
View
Buybacks
Authorized · 7 programs
$6.8B
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 4, 2026
This year
23

United Therapeutics reported $832.5 million in revenue for the quarter ended September 30, 2026, versus $799.5 million, while net income declined to $258.6 million from $338.7 million.

View
Proposed Sales
Value
$701.8K
Shares
1.2K
Filed
Nov 9, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 17, 2026
Last webcast
Nov 16, 2026
View
Investor Relations
Latest news
United Therapeutics Corporation R…
Published
Nov 4, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
UTHR +5.2% +10.9% +2.2% -1.3% +21.3%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +2.6% +12.1% +1.7% -1.1% +10.7%

Capital returns

Buyback programs · 7 active · as of Oct 21, 2026
Authorized (total)
$6.75B
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1082554 CUSIP 91307C102 13F (30d) 647 filings 596 filers Visit website Investor relations